用于治疗晚期胃癌的非铂类化疗：5-氟尿嘧啶、紫杉烷类和伊立替康。
Non-platinum-based chemotherapy for treatment of advanced gastric cancer: 5-fluorouracil, taxanes, and irinotecan.
作者信息
Kang Byung Woog, Kim Jong Gwang, Kwon Oh-Kyoung, Chung Ho Young, Yu Wansik
机构信息
Byung Woog Kang, Jong Gwang Kim, Department of Hematology/Oncology, Kyungpook National University Medical Center, Daegu 702-210, South Korea.
出版信息
World J Gastroenterol. 2014 May 14;20(18):5396-402. doi: 10.3748/wjg.v20.i18.5396.
Abstract
Despite numerous advances in treatment options, advanced gastric cancer (AGC) remains a major public health issue and the leading cause of cancer-related deaths. Cisplatin is one of the most effective broad-spectrum anticancer drugs for AGC and a doublet combination regimen of either cisplatin-based or 5-fluorouracil (5FU)-based chemotherapy is generally used for treatment of patients with AGC. However, there is still no consensus on the best regimen for treating AGC. Recently, various new chemotherapeutic agents, including oral 5FU, taxanes, and irinotecan, have been identified as improving the outcomes for AGC when used as a single agent or in combination with non-platinum chemotherapy. Nonetheless, it is still unclear whether non-platinum-based chemotherapy is a viable treatment option for patients with AGC. Accordingly, this review focuses on the efficacy and tolerability of non-platinum-based chemotherapy for patients with AGC.
摘要
尽管治疗方案取得了诸多进展，但晚期胃癌（AGC）仍然是一个重大的公共卫生问题，也是癌症相关死亡的主要原因。顺铂是治疗AGC最有效的广谱抗癌药物之一，基于顺铂或基于5-氟尿嘧啶（5FU）的化疗双联方案通常用于治疗AGC患者。然而，对于治疗AGC的最佳方案仍未达成共识。最近，各种新的化疗药物，包括口服5FU、紫杉烷和伊立替康，已被确定在单药使用或与非铂类化疗联合使用时可改善AGC的治疗效果。尽管如此，非铂类化疗对于AGC患者是否是一种可行的治疗选择仍不清楚。因此，本综述重点关注非铂类化疗对AGC患者的疗效和耐受性。
相似文献
1
Non-platinum-based chemotherapy for treatment of advanced gastric cancer: 5-fluorouracil, taxanes, and irinotecan.用于治疗晚期胃癌的非铂类化疗：5-氟尿嘧啶、紫杉烷类和伊立替康。
World J Gastroenterol. 2014 May 14;20(18):5396-402. doi: 10.3748/wjg.v20.i18.5396.
2
Modified FOLFOX-6 therapy for heavily pretreated advanced gastric cancer refractory to fluorouracil, irinotecan, cisplatin and taxanes: a retrospective study.氟尿嘧啶、伊立替康、顺铂和紫杉烷类药物治疗耐药的晚期胃癌患者的改良 FOLFOX-6 治疗：回顾性研究。
Jpn J Clin Oncol. 2012 Aug;42(8):686-90. doi: 10.1093/jjco/hys084. Epub 2012 Jun 11.
3
The efficacy and toxicity of irinotecan with leucovorin and bolus and continuous infusional 5-fluorouracil (FOLFIRI) as salvage therapy for patients with advanced gastric cancer previously treated with platinum and taxane-based chemotherapy regimens.伊立替康联合亚叶酸钙以及推注和持续输注5-氟尿嘧啶（FOLFIRI）作为挽救疗法，用于先前接受过铂类和紫杉烷类化疗方案治疗的晚期胃癌患者的疗效和毒性。
J Chemother. 2012 Aug;24(4):217-20. doi: 10.1179/1973947812Y.0000000020.
4
Salvage chemotherapy with irinotecan and cisplatin in patients with metastatic gastric cancer failing both 5-fluorouracil and taxanes.对于5-氟尿嘧啶和紫杉烷类治疗均失败的转移性胃癌患者，采用伊立替康和顺铂进行挽救性化疗。
Anticancer Drugs. 2005 Jul;16(6):621-5. doi: 10.1097/00001813-200507000-00005.
5
Association of fluoropyrimidines, platinum agents, taxanes, and irinotecan in any line of chemotherapy with survival in patients with advanced gastric cancer.氟嘧啶类、铂类药物、紫杉烷类和伊立替康联合化疗在任何一线治疗中与晚期胃癌患者的生存相关。
Gastric Cancer. 2011 Jun;14(2):155-60. doi: 10.1007/s10120-011-0019-3. Epub 2011 Feb 23.
6
Salvage chemotherapy with biweekly irinotecan, plus 5-fluorouracil and leucovorin in patients with advanced gastric cancer previously treated with fluoropyrimidine, platinum, and taxane.对于先前接受过氟嘧啶、铂类和紫杉烷治疗的晚期胃癌患者，采用每两周一次的伊立替康联合5-氟尿嘧啶和亚叶酸进行挽救化疗。
Am J Clin Oncol. 2008 Apr;31(2):151-6. doi: 10.1097/COC.0b013e31815878a2.
7
Chemotherapy for advanced gastric cancer.晚期胃癌的化疗
Cochrane Database Syst Rev. 2010 Mar 17(3):CD004064. doi: 10.1002/14651858.CD004064.pub3.
8
Irinotecan combined with 5-fluorouracil and leucovorin third-line chemotherapy after failure of fluoropyrimidine, platinum, and taxane in gastric cancer: treatment outcomes and a prognostic model to predict survival.伊立替康联合氟尿嘧啶和亚叶酸钙三线化疗治疗氟尿嘧啶、铂类和紫杉烷类药物治疗失败后的胃癌：疗效和预测生存的预后模型。
Gastric Cancer. 2013 Oct;16(4):581-9. doi: 10.1007/s10120-012-0227-5. Epub 2012 Dec 25.
9
Randomized phase II study of irinotecan, leucovorin and 5-fluorouracil (ILF) versus cisplatin plus ILF (PILF) combination chemotherapy for advanced gastric cancer.伊立替康、亚叶酸钙和5-氟尿嘧啶（ILF）对比顺铂联合ILF（PILF）治疗晚期胃癌的随机II期研究
Ann Oncol. 2008 Apr;19(4):729-33. doi: 10.1093/annonc/mdm502. Epub 2007 Dec 13.
10
The role of chemotherapy in unresectable or metastatic adenocarcinoma of the stomach and gastroesophageal junction.化疗在不可切除或转移性胃及胃食管交界腺癌中的作用。
Minerva Chir. 2017 Aug;72(4):317-333. doi: 10.23736/S0026-4733.17.07357-6. Epub 2017 Apr 14.
引用本文的文献
1
Comprehensive Analysis of Disulfidptosis-Related LncRNAs in Molecular Classification, Immune Microenvironment Characterization and Prognosis of Gastric Cancer.胃癌分子分类、免疫微环境特征及预后中与二硫化物诱导细胞死亡相关长链非编码RNA的综合分析
Biomedicines. 2023 Nov 28;11(12):3165. doi: 10.3390/biomedicines11123165.
2
Heterogeneity characterization of hepatocellular carcinoma based on the sensitivity to 5-fluorouracil and development of a prognostic regression model.基于对5-氟尿嘧啶敏感性的肝细胞癌异质性特征及预后回归模型的建立
Front Pharmacol. 2023 Sep 7;14:1252805. doi: 10.3389/fphar.2023.1252805. eCollection 2023.
3
USP14 inhibition regulates tumorigenesis by inducing apoptosis in gastric cancer.USP14 抑制通过诱导胃癌细胞凋亡来调节肿瘤发生。
BMB Rep. 2023 Aug;56(8):451-456. doi: 10.5483/BMBRep.2023-0063.
4
CD13 downregulation mediated by ubenimex inhibits autophagy to overcome 5-FU resistance by disturbing the EMP3/FAK/NF-κB pathway in gastric cancer cells.由乌苯美司介导的CD13下调通过干扰胃癌细胞中的EMP3/FAK/NF-κB途径抑制自噬，从而克服5-氟尿嘧啶耐药性。
Transl Cancer Res. 2022 Aug;11(8):2487-2500. doi: 10.21037/tcr-22-345.
5
In Vitro Evaluation of Antiproliferative Properties of Novel Organotin(IV) Carboxylate Compounds with Propanoic Acid Derivatives on a Panel of Human Cancer Cell Lines.新型有机锡（IV）羧酸酯化合物与丙酸酸衍生物对人癌细胞系的体外增殖抑制活性评价。
Molecules. 2021 May 27;26(11):3199. doi: 10.3390/molecules26113199.
6
Retrospective Cohort Study of Intraoperative Administration of Sustained-Release 5-Fluorouracil Implants in Advanced Gastric Cancer Patients.晚期胃癌患者术中给予缓释5-氟尿嘧啶植入剂的回顾性队列研究。
Front Pharmacol. 2021 Apr 13;12:659258. doi: 10.3389/fphar.2021.659258. eCollection 2021.
7
The effects of genomic polymorphisms in one-carbon metabolism pathways on survival of gastric cancer patients received fluorouracil-based adjuvant therapy.一碳代谢途径中的基因多态性对接受氟尿嘧啶辅助治疗的胃癌患者生存的影响。
Sci Rep. 2016 Jul 26;6:28019. doi: 10.1038/srep28019.
8
Circulating tumor cell count as a biomarker of a specific gastric cancer subgroup characterized by bone metastasis and/or disseminated intravascular coagulation - an early indicator of chemotherapeutic response.循环肿瘤细胞计数作为以骨转移和/或弥散性血管内凝血为特征的特定胃癌亚组的生物标志物——化疗反应的早期指标。
Oncol Lett. 2016 Feb;11(2):1294-1298. doi: 10.3892/ol.2015.4056. Epub 2015 Dec 24.
本文引用的文献
1
Platinum-based versus non-platinum-based chemotherapy as first line treatment of inoperable, advanced gastric adenocarcinoma: a meta-analysis.铂类与非铂类化疗作为不可切除的晚期胃腺癌一线治疗：一项荟萃分析。
PLoS One. 2013 Jul 11;8(7):e68974. doi: 10.1371/journal.pone.0068974. Print 2013.
2
Current questions for the treatment of advanced gastric cancer.当前晚期胃癌治疗的问题。
Cancer Treat Rev. 2013 Feb;39(1):60-7. doi: 10.1016/j.ctrv.2012.09.007. Epub 2012 Oct 25.
3
Cisplatin resistance: a cellular self-defense mechanism resulting from multiple epigenetic and genetic changes.顺铂耐药性：一种由多种表观遗传和遗传变化引起的细胞自我保护机制。
Pharmacol Rev. 2012 Jul;64(3):706-21. doi: 10.1124/pr.111.005637. Epub 2012 Jun 1.
4
Phase II multi-institutional prospective randomised trial comparing S-1+paclitaxel with S-1+cisplatin in patients with unresectable and/or recurrent advanced gastric cancer.Ⅱ期多机构前瞻性随机试验比较 S-1+紫杉醇与 S-1+顺铂治疗不可切除和/或复发性晚期胃癌患者。
Br J Cancer. 2012 Jun 26;107(1):31-6. doi: 10.1038/bjc.2012.222. Epub 2012 May 22.
5
Management of advanced gastric cancer.晚期胃癌的治疗。
Expert Rev Gastroenterol Hepatol. 2012 Apr;6(2):199-208; quiz 209. doi: 10.1586/egh.11.103.
6
Phase 2 study of capecitabine and irinotecan combination chemotherapy (modified XELIRI regimen) in patients with advanced gastric cancer.卡培他滨和伊立替康联合化疗（改良 XELIRI 方案）治疗晚期胃癌的Ⅱ期研究。
Am J Clin Oncol. 2011 Dec;34(6):555-60. doi: 10.1097/COC.0b013e3181f47ac1.
7
The role of chemotherapy in metastatic gastric cancer.化疗在转移性胃癌中的作用。
Anticancer Res. 2011 Oct;31(10):3543-54.
8
Capecitabine for the treatment for advanced gastric cancer: efficacy, safety and ethnicity.卡培他滨治疗晚期胃癌：疗效、安全性和种族差异。
J Clin Pharm Ther. 2012 Jun;37(3):266-75. doi: 10.1111/j.1365-2710.2011.01289.x. Epub 2011 Sep 26.
9
A comprehensive review of S-1 in the treatment of advanced gastric adenocarcinoma.S-1 治疗晚期胃腺癌的全面综述。
Future Oncol. 2011 Jun;7(6):715-26. doi: 10.2217/fon.11.50.
10
A randomized phase 2 study of docetaxel and S-1 versus docetaxel and cisplatin in advanced gastric cancer with an evaluation of SPARC expression for personalized therapy.一项评估 SPARC 表达用于个体化治疗的多西他赛和 S-1 对比多西他赛和顺铂治疗晚期胃癌的随机 2 期研究。
Cancer. 2011 May 15;117(10):2050-7. doi: 10.1002/cncr.25729. Epub 2010 Nov 29.
Zotero 插件